Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Preview text: Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update…

Monday, Aug 31, 2026 at 7:00 PM EasternMailchimp

Rakovina TherapeuticsRakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Fit to screenFull size

Using this email in an article? Credit: Rakovina Therapeutics email via They Sent It, with a link to this page. Full-size image

Use this example

Subject: Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
Preview text: Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update…
From: ir@rakovinatherapeutics.com
Brand: Rakovina Therapeutics
ESP: Mailchimp
Sent: Mon Aug 31, 2026, 7:00 PM ET
Size: 76 KB
Images: 7
Links: 10, 2 of them buttons
Subject length: 87 characters

Against Rakovina Therapeutics's usual

Sent in the 7 PM hour, which holds 6% of its emails; 31% arrive in the 4 PM hour. The subject is 87 characters; its average is 70.

Email headers

What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.

From: Rakovina Therapeutics <[email protected]>
Reply-To: Rakovina Therapeutics <[email protected]>
Subject: Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
Date: Mon, 31 Aug 2026 23:00:50 +0000
Message-ID domain: mail148.suw161.rsgsv.net
Return-Path domain: mail148.suw161.rsgsv.net
DKIM signature: d=mailchimpapp.net s=k3
List-Unsubscribe: Present, one-click
Mailer: Mailchimp Mailer
Feedback-ID sender: mc

Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype

	Oct 1, 2026 4:18 PM	Rakovina partners with Celvion: what it means for our ATR program
	Sep 17, 2026 4:45 AM	Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
	Sep 10, 2026 4:30 AM	Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors
	Aug 31, 2026 7:00 PM	Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update (this email)
	Aug 31, 2026 4:42 PM	Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement
	Aug 19, 2026 7:01 AM	Rakovina Therapeutics Announces Results from 2026 Annual General Meeting
	Aug 12, 2026 4:30 AM	Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement